Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | TYR | P14679 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401422 | 0.79 | ESR1 (0.54) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL57086 | 0.78 | ALDH1A1 (0.46) | ESR1ALDH1A1ABCG2MEN1KMT2A | |
| SCHEMBL7923836 | 0.76 | CYP1A2 (0.46) | CA1CA2TYRKDM4EALDH1A1 | |
| SCHEMBL3519645 | 0.74 | KDM4E (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8713174 | 0.73 | ESR1 (0.47) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL5607421 | 0.73 | ABCG2 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11334254 | 0.73 | ABCG2 (0.61) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL11334255 | 0.73 | ABCG2 (0.61) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL9335450 | 0.73 | KDM4E (0.55) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL5607425 | 0.73 | ABCG2 (0.61) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119111-A2 | MORPHIC FORMS OF A MUTANT BRAF DEGRADER AND METHODS OF MANUFACTURE THEREOF | C4 THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
| EP-2822944-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN, INC. (US) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013134079-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013134754-A1 | A METHOD FOR PRODUCING BIOBASED CHEMICALS FROM PLANT LIGNIN | Vertichem Corporation (CA) | 2013-09-12 | — | — | WO | disclosed |
| US-5188866-A | Recording coating of ferromagnetic metal and polymer; corrosion resistance | KAO CORPORATION (JP) | 1993-02-23 | — | — | US | disclosed |
| US-5080982-A | Magnetic recording medium | KAO CORPORATION (JP) | 1992-01-14 | — | — | US | disclosed |
| EP-0268075-B1 | ELECTROPLATED COMPOSITE OF ZINC AND ORGANIC POLYMER | Kao Corporation (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-4797183-A | POLYMER CONTAINING CARBOXY OR PHOSPHORUS ACID GROUP | KAO CORPORATION (JP) | 1989-01-10 | — | — | US | disclosed |
| EP-0268075-A1 | Electroplated composite of zinc and organic polymer | Kao Corporation (JP) | 1988-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | ESR1 3622/4885ESR2 4465/4885CA12 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.